DEF: Vaxart Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Vaxart is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and elect six directors at the upcoming annual meeting.

Summary

• Vaxart, Inc. is holding its 2025 Annual Meeting of Stockholders on May 21, 2025, via live webcast.
• Stockholders will vote on several proposals, including the election of six directors, an amendment to the Restated Certificate of Incorporation to effect a reverse stock split, ratification of the selection of WithumSmith+Brown, PC as the independent registered public accounting firm, and an advisory vote on executive compensation.
• The proposed reverse stock split would allow the board of directors to combine issued shares of common stock by a ratio of not less than 1-for-5 and not more than 1-for-50, with the exact ratio to be determined by the board.
• The company is seeking the reverse stock split to maintain compliance with Nasdaq listing requirements, potentially increase investor interest, and attract and retain employees.
• The record date for the Annual Meeting is March 26, 2025.
• As of the record date, there were 228,208,284 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily conveying information about the upcoming annual meeting and proposals. The need for a reverse stock split introduces a slightly negative element, but the overall sentiment is balanced.

Positives

• The reverse stock split could help Vaxart maintain its Nasdaq listing.
• A higher stock price resulting from the reverse stock split may increase investor interest and trading volume.
• The company believes a higher stock price may help attract and retain employees.
• The board of directors is actively involved in overseeing the management of Vaxart's risks.
• The company has a Compensation Recovery Policy in place.

Negatives

• The reverse stock split may not result in an increase in the per share price of the common stock.
• The market price of the common stock will also be based on performance of the company and other factors, some of which are unrelated to the number of shares outstanding.
• The liquidity of the common stock could be adversely affected by the reduced number of shares outstanding after the reverse stock split.
• Zosano Pharma Corporation, where Steven Lo served as CEO, filed for bankruptcy in 2022.

Risks

• There is no guarantee that the reverse stock split will increase the market price of Vaxart's common stock.
• The company may not be able to regain compliance with the Nasdaq's minimum bid price requirement.
• The listing of Vaxart's shares on The Nasdaq Capital Market may be halted or discontinued if the company is unable to maintain compliance with any other Nasdaq continued listing requirement for any reason.
• The market price of Vaxart's common stock will also be based on performance of the company and other factors, some of which are unrelated to the number of shares outstanding.
• If the reverse stock split is effected and the market price of the common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of the company may be greater than would occur in the absence of a reverse stock split.
• The liquidity of the common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.

Future Outlook

The company intends to hold the Annual Meeting in a virtual-format only via live webcast and encourages stockholders to monitor the Investor Relations section of its website for updated information.

Industry Context

The document relates to corporate governance matters typical for publicly traded companies, particularly those seeking to maintain listing compliance.

Comparison to Industry Standards

• The peer group for compensation benchmarking includes companies like Adverum Biotechnologies, Allakos, Altimmune, Arcturus Therapeutics, and others, reflecting a focus on pre-commercial biopharmaceutical companies.
• The compensation structure aims for the 25th to 50th percentile of market data, aligning with common industry practices for executive compensation.
• The director compensation program includes cash retainers and equity awards, which is a standard approach in the biotechnology industry.

Management Changes

Related Party Transactions

• The company has entered into indemnity agreements with its executive officers and directors.
• The company has entered into letter agreements, employment agreements and change in control arrangements with its executive officers.
• The company granted stock options to its executive officers and members of its board of directors.

Stakeholder Impact

• The reverse stock split could impact shareholders by potentially increasing the stock price and maintaining the Nasdaq listing.
• Executive compensation decisions impact shareholders and employees.
• The election of directors will determine the leadership and direction of the company.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The board of directors will determine the exact ratio for the reverse stock split if approved.
• The company will file the Reverse Stock Split Charter Amendment with the Secretary of State of the State of Delaware if the board decides to proceed with the reverse stock split.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, Nasdaq, directors, executive compensation, Vaxart, VXRT, stockholders